OrthoPediatrics reports record FY2024 revenue of $204.7M, up 38% YoY; Q4 adjusted EBITDA doubles to $3.0M

ORTHOPEDIATRICS CORP

Full year 2024 revenue $204.7M, up 38% from $148.7M in 2023; Q4 revenue $52.7M, up 40% YoY.
Full year adjusted EBITDA $8.5M vs $5.0M in 2023; Q4 adjusted EBITDA $3.0M, more than double $1.3M.
Net loss widened to $37.8M in 2024 from $21.0M in 2023; Q4 net loss $16.1M ($0.69/sh) vs $6.7M ($0.29/sh).
FY2025 guidance: revenue $235-242M (15-18% growth), adjusted EBITDA $15-17M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.